Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome

The Northern Manhattan Study

Barry Hudson, Chuanhui Dong, Hannah Gardener, Mitchell S V Elkind, Clinton B Wright, Ronald B Goldberg, Ralph L Sacco, Tatjana Rundek

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective Recent studies have shown a strong link between serum soluble receptor for advanced glycation end-products (sRAGE) levels and cardiovascular risk factors and disease. What is less clear is the relationship between metabolic risk factors and sRAGE levels. Here, we tested the hypothesis that lower sRAGE levels may be associated with the metabolic syndrome (MetS) in an urban multi ethnic population. Materials/methods From the Northern Manhattan Study (NOMAS), we included 1101 stroke-free participants (mean age: 71 ± 9 years, 60% women, 64% Hispanic, 18% black, 16% white). Serum sRAGE was measured by ELISA. Quantile regression analysis was performed to evaluate the association between sRAGE and MetS components and MetS, after adjusting for sociodemographics, smoking status and kidney function. Results The median (interquartile) sRAGE was 899 pg/ml (647-1248 pg/ml), 42% had metabolic syndrome. The prevalence of unfavorable metabolic factors was 50% for waist circumference (WC), 81% for blood pressure, 39% for fasting glucose, 35% for reduced high density lipoproteins (HDL), and 23% for triglycerides. After adjustment, the median sRAGE levels were at least 120 pg/ml lower in those who had elevated WC (p < 0.0001), blood pressure (p = 0.0014), and fasting glucose (p < 0.0001), and those who had 2 or more unfavorable metabolic factors. No relationship was seen between sRAGE levels and elevated triglycerides or reduced HDL levels. Interaction and stratified analyses revealed that the association of sRAGE with MetS was more prominent in Hispanics compared to whites, and displaying no association with components of MetS in blacks. Conclusions sRAGE levels were mainly associated with MetS factors related to obesity, diabetes and hypertension, and displayed variation with ethnicity in a multi-ethnic population. Further studies of sRAGE, MetS and their relationship to cardiovascular disease are warranted.

Original languageEnglish
Pages (from-to)1125-1130
Number of pages6
JournalMetabolism: Clinical and Experimental
Volume63
Issue number9
DOIs
StatePublished - Jan 1 2014

Fingerprint

Serum
Waist Circumference
HDL Lipoproteins
Hispanic Americans
Fasting
Triglycerides
Advanced Glycosylation End Product-Specific Receptor
Blood Pressure
Social Adjustment
Glucose
Population
Cardiovascular Diseases
Obesity
Smoking
Enzyme-Linked Immunosorbent Assay
Stroke
Regression Analysis
Hypertension
Kidney

Keywords

  • Biomarker
  • Cardiovascular disease
  • Diabetes
  • Metabolic syndrome
  • RAGE

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome : The Northern Manhattan Study. / Hudson, Barry; Dong, Chuanhui; Gardener, Hannah; Elkind, Mitchell S V; Wright, Clinton B; Goldberg, Ronald B; Sacco, Ralph L; Rundek, Tatjana.

In: Metabolism: Clinical and Experimental, Vol. 63, No. 9, 01.01.2014, p. 1125-1130.

Research output: Contribution to journalArticle

@article{fecfbf0b6964450bac3ee25d1e12998e,
title = "Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: The Northern Manhattan Study",
abstract = "Objective Recent studies have shown a strong link between serum soluble receptor for advanced glycation end-products (sRAGE) levels and cardiovascular risk factors and disease. What is less clear is the relationship between metabolic risk factors and sRAGE levels. Here, we tested the hypothesis that lower sRAGE levels may be associated with the metabolic syndrome (MetS) in an urban multi ethnic population. Materials/methods From the Northern Manhattan Study (NOMAS), we included 1101 stroke-free participants (mean age: 71 ± 9 years, 60{\%} women, 64{\%} Hispanic, 18{\%} black, 16{\%} white). Serum sRAGE was measured by ELISA. Quantile regression analysis was performed to evaluate the association between sRAGE and MetS components and MetS, after adjusting for sociodemographics, smoking status and kidney function. Results The median (interquartile) sRAGE was 899 pg/ml (647-1248 pg/ml), 42{\%} had metabolic syndrome. The prevalence of unfavorable metabolic factors was 50{\%} for waist circumference (WC), 81{\%} for blood pressure, 39{\%} for fasting glucose, 35{\%} for reduced high density lipoproteins (HDL), and 23{\%} for triglycerides. After adjustment, the median sRAGE levels were at least 120 pg/ml lower in those who had elevated WC (p < 0.0001), blood pressure (p = 0.0014), and fasting glucose (p < 0.0001), and those who had 2 or more unfavorable metabolic factors. No relationship was seen between sRAGE levels and elevated triglycerides or reduced HDL levels. Interaction and stratified analyses revealed that the association of sRAGE with MetS was more prominent in Hispanics compared to whites, and displaying no association with components of MetS in blacks. Conclusions sRAGE levels were mainly associated with MetS factors related to obesity, diabetes and hypertension, and displayed variation with ethnicity in a multi-ethnic population. Further studies of sRAGE, MetS and their relationship to cardiovascular disease are warranted.",
keywords = "Biomarker, Cardiovascular disease, Diabetes, Metabolic syndrome, RAGE",
author = "Barry Hudson and Chuanhui Dong and Hannah Gardener and Elkind, {Mitchell S V} and Wright, {Clinton B} and Goldberg, {Ronald B} and Sacco, {Ralph L} and Tatjana Rundek",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.metabol.2014.05.011",
language = "English",
volume = "63",
pages = "1125--1130",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome

T2 - The Northern Manhattan Study

AU - Hudson, Barry

AU - Dong, Chuanhui

AU - Gardener, Hannah

AU - Elkind, Mitchell S V

AU - Wright, Clinton B

AU - Goldberg, Ronald B

AU - Sacco, Ralph L

AU - Rundek, Tatjana

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective Recent studies have shown a strong link between serum soluble receptor for advanced glycation end-products (sRAGE) levels and cardiovascular risk factors and disease. What is less clear is the relationship between metabolic risk factors and sRAGE levels. Here, we tested the hypothesis that lower sRAGE levels may be associated with the metabolic syndrome (MetS) in an urban multi ethnic population. Materials/methods From the Northern Manhattan Study (NOMAS), we included 1101 stroke-free participants (mean age: 71 ± 9 years, 60% women, 64% Hispanic, 18% black, 16% white). Serum sRAGE was measured by ELISA. Quantile regression analysis was performed to evaluate the association between sRAGE and MetS components and MetS, after adjusting for sociodemographics, smoking status and kidney function. Results The median (interquartile) sRAGE was 899 pg/ml (647-1248 pg/ml), 42% had metabolic syndrome. The prevalence of unfavorable metabolic factors was 50% for waist circumference (WC), 81% for blood pressure, 39% for fasting glucose, 35% for reduced high density lipoproteins (HDL), and 23% for triglycerides. After adjustment, the median sRAGE levels were at least 120 pg/ml lower in those who had elevated WC (p < 0.0001), blood pressure (p = 0.0014), and fasting glucose (p < 0.0001), and those who had 2 or more unfavorable metabolic factors. No relationship was seen between sRAGE levels and elevated triglycerides or reduced HDL levels. Interaction and stratified analyses revealed that the association of sRAGE with MetS was more prominent in Hispanics compared to whites, and displaying no association with components of MetS in blacks. Conclusions sRAGE levels were mainly associated with MetS factors related to obesity, diabetes and hypertension, and displayed variation with ethnicity in a multi-ethnic population. Further studies of sRAGE, MetS and their relationship to cardiovascular disease are warranted.

AB - Objective Recent studies have shown a strong link between serum soluble receptor for advanced glycation end-products (sRAGE) levels and cardiovascular risk factors and disease. What is less clear is the relationship between metabolic risk factors and sRAGE levels. Here, we tested the hypothesis that lower sRAGE levels may be associated with the metabolic syndrome (MetS) in an urban multi ethnic population. Materials/methods From the Northern Manhattan Study (NOMAS), we included 1101 stroke-free participants (mean age: 71 ± 9 years, 60% women, 64% Hispanic, 18% black, 16% white). Serum sRAGE was measured by ELISA. Quantile regression analysis was performed to evaluate the association between sRAGE and MetS components and MetS, after adjusting for sociodemographics, smoking status and kidney function. Results The median (interquartile) sRAGE was 899 pg/ml (647-1248 pg/ml), 42% had metabolic syndrome. The prevalence of unfavorable metabolic factors was 50% for waist circumference (WC), 81% for blood pressure, 39% for fasting glucose, 35% for reduced high density lipoproteins (HDL), and 23% for triglycerides. After adjustment, the median sRAGE levels were at least 120 pg/ml lower in those who had elevated WC (p < 0.0001), blood pressure (p = 0.0014), and fasting glucose (p < 0.0001), and those who had 2 or more unfavorable metabolic factors. No relationship was seen between sRAGE levels and elevated triglycerides or reduced HDL levels. Interaction and stratified analyses revealed that the association of sRAGE with MetS was more prominent in Hispanics compared to whites, and displaying no association with components of MetS in blacks. Conclusions sRAGE levels were mainly associated with MetS factors related to obesity, diabetes and hypertension, and displayed variation with ethnicity in a multi-ethnic population. Further studies of sRAGE, MetS and their relationship to cardiovascular disease are warranted.

KW - Biomarker

KW - Cardiovascular disease

KW - Diabetes

KW - Metabolic syndrome

KW - RAGE

UR - http://www.scopus.com/inward/record.url?scp=84906264692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906264692&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2014.05.011

DO - 10.1016/j.metabol.2014.05.011

M3 - Article

VL - 63

SP - 1125

EP - 1130

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 9

ER -